Abstract | OBJECTIVES: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices of sofosbuvir and daclatasvir. METHODS: Data on per-kilogram prices of sofosbuvir and daclatasvir active pharmaceutical ingredients (API) exported from India were extracted from an online database. To the cost of the amount of API needed for a 12-week treatment course, we added cost estimates for formulation (40%), packaging (US$0.35/month), and a mark-up (50%). RESULTS: Between 1 January and 15 October 2015, over 5 tons of sofosbuvir were exported, with prices decreasing by US$702/kg/month, and observed prices of US$2501/kg in early September. Over the same period, 84 kg of daclatasvir were exported, with prices decreasing by US$1664/kg/month to US$1897/kg. Using the price estimation algorithm, we estimated the price of a generic sofosbuvir- daclatasvir combination regimen at US$200 per patient for a 12-week treatment course. CONCLUSION:
|
Authors | Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak |
Journal | Journal of virus eradication
(J Virus Erad)
Vol. 2
Issue 1
Pg. 28-31
(Jan 01 2016)
ISSN: 2055-6640 [Print] England |
PMID | 27482432
(Publication Type: Journal Article)
|